Future watch
Market area:

Future of Hospital, case Russia

Material based on Future Watch foresight session of Team Finland Russia about Digital healthcare development in the country.

Trends: Telemedicine business is expected to boom in Russia since Q1 2017 catalyzed by legislative changes. Target is set to have 25% of all medical organizations to be able to provide telemedicine services in 2018. Telemedicine attracts newcomers with large databases of loyal clients to disrupt DH market: banks (Sberbank. Alfabank); mobile operators (MTS, Megafon, Beeline); Social networks (VK, Odnoklassniki), Internet companies (Yandex, Mail.ru); Insurance companies. Attempts to reverse Russian medical tourism, that leaves $2 Bn abroad each year, by creating local alternative - international medical cluster in Skolkovo by Moscow City government. Growing interest in IoT solutions for concealed and insensible patient monitoring (gas sensors, IR cameras, etc), combined in a network armed with AI to assist doctors in alarming potential health issues. Yet shall provide high quality to be certified for evidence-based healthcare. New law on “biomedical cell products” coming in force in 2017. The law regulates all types of R&D related to human cells, with a range of definitions for cell lines, biomedical cell product, cell donor, etc made legally for the first time in Russia – creating basis for biobanks development in Russia. New regulations on Big Data control and ownership are under discussion in the government, inspired by cybersecurity companies like InfoWatch. Open data provision to foreign companies is questioned.

Very early stage DH market means little competition for Finnish (and other) companies. Big room for new technologies and products. Growing interest from Russian VC community to invest in DH solutions that can demonstrate proven business models, for example services attracting large groups of subscribers or clear cost reduction in patient care. Quick growth expectations for telemedicine market. International Medical Cluster and Biocity in Skolkovo as test beds and softlanding spots in
Russia. Development of biobanks. Market not monopolized by any industry leader and well suited for foreign (Finnish) SMEs. Good opportunities for
cooperation with local companies.

Full material (presentation) is available upon request!

Average (0 Votes)
No comments yet. Be the first.